» Articles » PMID: 30347872

PG-Priming Enhances Doxorubicin Influx to Trigger Necrotic and Autophagic Cell Death in Oral Squamous Cell Carcinoma

Overview
Journal J Clin Med
Specialty General Medicine
Date 2018 Oct 24
PMID 30347872
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Synergistic effects between natural compounds and chemotherapy drugs are believed to have fewer side effects with equivalent efficacy. However, the synergistic potential of prodigiosin (PG) with doxorubicin (Dox) chemotherapy is still unknown. This study explores the synergistic mechanism of PG and Dox against oral squamous cell carcinoma (OSCC) cells. Three OSCC cell lines were treated with different PG/Dox combinatory schemes for cytotoxicity tests and were further investigated for cell death characteristics by cell cycle flow cytometry and autophagy/apoptosis marker labelling. When OSCC cells were pretreated with PG, the cytotoxicity of the subsequent Dox-treatment was 30% higher than Dox alone. The cytotoxic efficacy of PG-pretreated was found better than those of PG plus Dox co-treatment and Dox-pretreatment. Increase of Sub-G1 phase and caspase-3/LC-3 levels without poly (ADP-ribose) polymeras (PARP) elevation indicated both autophagy and necrosis occurred in OSCC cells. Dox flux after PG-priming was further evaluated by rhodamine-123 accumulation and Dox transporters analysis to elucidate the PG-priming effect. PG-priming autophagy enhanced Dox accumulation according to the increase of rhodamine-123 accumulation without the alterations of Dox transporters. Additionally, the cause of PG-triggered autophagy was determined by co-treatment with endoplasmic reticulum (ER) stress or AMP-activated protein kinase (AMPK) inhibitor. PG-induced autophagy was not related to nutrient deprivation and ER stress was proved by co-treatment with specific inhibitor. Taken together, PG-priming autophagy could sensitize OSCC cells by promoting Dox influx without regulation of Dox transporter. The PG-priming might be a promising adjuvant approach for the chemotherapy of OSCC.

Citing Articles

The Golgi stacking protein GRASP55 is targeted by the natural compound prodigiosin.

Berning L, Lenz T, Bergmann A, Poschmann G, Brass H, Schlutermann D Cell Commun Signal. 2023; 21(1):275.

PMID: 37798768 PMC: 10552397. DOI: 10.1186/s12964-023-01275-1.


Prodigiosin from Serratia Marcescens in Cockroach Inhibits the Proliferation of Hepatocellular Carcinoma Cells through Endoplasmic Reticulum Stress-Induced Apoptosis.

Wang J, Liu H, Zhu L, Wang J, Luo X, Liu W Molecules. 2022; 27(21).

PMID: 36364107 PMC: 9653855. DOI: 10.3390/molecules27217281.


Bacterial pigments: A colorful palette reservoir for biotechnological applications.

Orlandi V, Martegani E, Giaroni C, Baj A, Bolognese F Biotechnol Appl Biochem. 2021; 69(3):981-1001.

PMID: 33870552 PMC: 9544673. DOI: 10.1002/bab.2170.


Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment.

Berning L, Schlutermann D, Friedrich A, Berleth N, Sun Y, Wu W Molecules. 2021; 26(5).

PMID: 33673611 PMC: 7957586. DOI: 10.3390/molecules26051294.


Doxorubicin metabolism moderately attributes to putative toxicity in prodigiosin/doxorubicin synergism in vitro cells.

Lin S, Lin C, Chen C, Tseng F, Wu T, Weng L Mol Cell Biochem. 2020; 475(1-2):119-126.

PMID: 32754875 PMC: 7599147. DOI: 10.1007/s11010-020-03864-x.


References
1.
Lapenda J, Silva P, Vicalvi M, Sena K, Nascimento S . Antimicrobial activity of prodigiosin isolated from Serratia marcescens UFPEDA 398. World J Microbiol Biotechnol. 2015; 31(2):399-406. DOI: 10.1007/s11274-014-1793-y. View

2.
Darshan N, Manonmani H . Prodigiosin and its potential applications. J Food Sci Technol. 2015; 52(9):5393-407. PMC: 4554646. DOI: 10.1007/s13197-015-1740-4. View

3.
Geretti E, Leonard S, Dumont N, Lee H, Zheng J, De Souza R . Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). Mol Cancer Ther. 2015; 14(9):2060-71. DOI: 10.1158/1535-7163.MCT-15-0314. View

4.
Thiyagarajan V, Lin S, Lee C, Weng C . A focal adhesion kinase inhibitor 16-hydroxy-cleroda-3,13-dien-16,15-olide incorporated into enteric-coated nanoparticles for controlled anti-glioma drug delivery. Colloids Surf B Biointerfaces. 2016; 141:120-131. DOI: 10.1016/j.colsurfb.2016.01.038. View

5.
Gupta B, Ramasamy T, Poudel B, Pathak S, Regmi S, Choi J . Development of Bioactive PEGylated Nanostructured Platforms for Sequential Delivery of Doxorubicin and Imatinib to Overcome Drug Resistance in Metastatic Tumors. ACS Appl Mater Interfaces. 2017; 9(11):9280-9290. DOI: 10.1021/acsami.6b09163. View